UpToDate

THE MOAT IS THE DATASET PRECEDENT AT ITS MAXIMUM STRENGTH, and the company frames it that way itself, calling Expert AI the next evolution of UpToDate and stating that it is built solely on the existing curated corpus. The asset is more than thirty years of content maintained by over 7,600 physician authors and editors and used by a reported three million clinicians. Remove the generative layer and what remains is the market leading clinical decision support product, which is what it was until September 2025. THE GRADE DESCRIBES THE RELATIONSHIP BETWEEN THE MECHANISM AND THE MOAT, NOT THE SOPHISTICATION OF THE ENGINEERING, and that distinction needs stating plainly on this record: the AI work here is more advanced than at several vendors graded B in this index, with a stated multi layer validation framework, an assumptions and rationale architecture, and a named enterprise model partnership. It is graded C because a buyer removing the model still holds almost all of the value, which is the opposite of the position at a vendor like Kinometrix where removing the model leaves nothing.

**THE BEST OVERSIGHT ARCHITECTURE FOR A GENERATIVE CLINICAL PRODUCT IN THIS INDEX, AND IT EARNS THE GRADE ON TWO MECHANISMS NOTHING ELSE HERE HAS.** FIRST, THE ASSUMPTIONS BLOCK: every response opens by naming what the system took for granted about the patient, in the vendor's own illustration that the patient is not pregnant, not a child and has no major comorbidities. A model that states its own premises before answering lets a clinician invalidate the answer in one glance rather than reading to the end to discover it was answering a different question. SECOND, AND MORE IMPORTANT, THE NUDGES: inline prompts asking the clinician to supply context the system lacks, such as comorbidities or ICU status. **THIS INDEX ASKS NEARLY EVERY VENDOR WHAT ITS SYSTEM DOES WHEN IT DOES NOT KNOW, AND ALMOST NEVER GETS AN ANSWER. This is a real answer and a different shape from the one expected: rather than abstaining or emitting a confidence score, the system names the gap and asks the user to close it.** Set alongside the Cytovale IntelliSep intermediate band as the index's two worked examples of handling uncertainty honestly. Supported by inline citations tied to specific statements and by positioning that customers themselves endorse, one quoted preferring supportive decisions over automated ones. ONE COUNTERWEIGHT RECORDED AND PRECISELY ATTRIBUTED: trade coverage of the launch reported the company as saying that closing the system to the broader web eliminates the chance of hallucination. That claim does not appear on the product page, which uses the more careful language of grounding and traceability, but if it is made in a sales setting it is an overclaim, because grounding constrains the source material without eliminating synthesis error, and telling clinicians a tool cannot hallucinate is precisely the message that lowers the scrutiny this architecture is otherwise designed to support.

Strong on provenance and reasoning, silent on the model itself. WHAT IS PUBLISHED IS UNUSUAL AND CREDITABLE: every answer carries inline citations tied to specific statements with single click access to the source UpToDate topic, a side panel exposing rationale and supporting material, and a stated assumptions block. Wolters Kluwer NAMED OPENAI AS ITS ENTERPRISE MODEL PARTNER in June 2026, which is a disclosure C8 Health and Curbside Health both decline to make and which lets a buyer reason about the underlying technology at all. The company has also published a validation framework for evaluating clinical AI at the point of care and a whitepaper on the approach, plus an insight piece arguing that clinical AI evaluation must go beyond benchmark wins. WHAT IS ABSENT IS EVERY NUMBER. No model class or version, no evaluation results, no hallucination or error rate, no benchmark performance, and no published output of the validation framework the company itself designed. PUBLISHING A FRAMEWORK AND WITHHOLDING ITS RESULTS IS A DISTINCT POSTURE WORTH NAMING, and it is what separates this from an A.

GRADED ON WHAT WAS RETRIEVED, AND THE RETRIEVAL GAP IS STATED EXPLICITLY BECAUSE IT MATTERS MORE HERE THAN ON MOST RECORDS. What was located this pass is vendor produced or vendor promoted: whitepapers on evaluating clinical AI, a published validation framework, an Outsell analyst report the company promotes as independent validation, Wolters Kluwer surveys of physicians, and named customer testimony from St. Luke's University Health Network and the University of Texas Medical Branch. No published evaluation of Expert AI's accuracy, no error rate, and no peer reviewed study of the generative product was found. **IMPORTANT CAVEAT FOR ANY REFRESH: UpToDate maintains a Research Studies page and the underlying content product has an older peer reviewed outcomes literature associating its use with hospital level outcomes, NONE OF WHICH WAS RETRIEVED IN THIS PASS. That literature was not assessed and is not reflected in this grade.** Pull it specifically on refresh, because this axis could move materially and the absence here is a retrieval limit rather than an established evidentiary gap.

A privacy and cookies policy and terms of use are published and linked, and NEITHER WAS OPENED THIS PASS, recorded explicitly per the Droxi and Sickbay lesson rather than left implicit. THE PRODUCT SPECIFIC QUESTION IS LIVE AND UNANSWERED FROM ANYTHING READ. Expert AI is a conversational interface that invites clinicians to describe cases in natural language and prompts them to add comorbidities and ICU status, so free text clinical detail about identifiable patients will predictably be typed into it, and the product is also reachable from inside Epic. Nothing located states whether queries are retained, for how long, whether they are used to improve the service or the underlying models, or how the answer differs between a personal subscription bought with a credit card and an enterprise deployment under a health system agreement. That last distinction matters more here than at most vendors because the same product is sold both ways.

No HIPAA statement, business associate agreement terms, tier or execution path was located in the material read this pass. Not Rated means no public evidence was found, not evidence of weakness, and that framing is doing real work here: Wolters Kluwer is a listed multinational selling into thousands of hospitals, so contractual and compliance documentation certainly exists and was simply not searched for in this pass. FLAGGED FOR REFRESH as a known retrieval gap rather than a finding.

No SOC 2 of any type, no HITRUST, no ISO 27001 and no trust centre was located in the material read this pass. As with the HIPAA axis, Not Rated here reflects a retrieval limit rather than an established absence: a listed multinational operating in more than thirty countries and integrated into Epic will hold security attestations, and the company publishes an ISO 27000 explainer in another division. FLAGGED FOR REFRESH. Worth noting for contrast that C8 Health, a company a fraction of the size in the same segment, publishes SOC 2 Type II with the type specified and runs a public trust centre, so scale is not the reason this is unrated.

No FDA clearance, none claimed, and none apparently required. The grade records the absence; the note records that the regulatory position is strong and that this product illustrates the underlying test better than most. THE CLINICAL DECISION SUPPORT EXCLUSION TURNS ON WHETHER A CLINICIAN CAN INDEPENDENTLY REVIEW THE BASIS FOR A RECOMMENDATION, and here the basis is an inline citation to a specific expert authored topic, alongside a stated set of assumptions and a rationale panel. The clinician can read the source, see what was assumed and follow the reasoning. That is the same structural position as C8 Health and Curbside Health and the direct inverse of the Epic Sepsis Model. The company never states a regulatory rationale explicitly, so ask for it directly, and ask specifically how the position is maintained as the product moves toward the agentic capabilities named in the OpenAI collaboration, since an agent that acts is a different regulatory object from a reference that answers.

B rests on published artefacts rather than assertions, which is the same basis on which CLEW earned this grade for its change control plan. Wolters Kluwer publishes a corporate AI principles statement, has RELEASED A VALIDATION FRAMEWORK FOR EVALUATING CLINICAL AI AT THE POINT OF CARE as a public document, and has published a whitepaper describing how Expert AI is assessed for clinical usefulness, knowledge integrity and potential risks, plus an insight piece arguing that clinical AI evaluation must go beyond benchmark wins. The company also publishes survey research on Shadow AI risk inside healthcare organisations, which is self interested but genuinely useful and is an unusual thing for a vendor to fund. THE GAP IS THAT THE FRAMEWORK IS PUBLISHED AND ITS RESULTS ARE NOT. No subgroup analysis, no performance by specialty or question type, no error taxonomy and no measured output of the company's own evaluation method appear anywhere. A SECOND EXPOSURE IS STRUCTURAL AND UNADDRESSED: the corpus is authored by 7,600 experts through an editorial process, so whatever is under represented in that editorial tradition is under represented in every answer the generative layer produces, and grounding to a curated corpus inherits the corpus's blind spots as faithfully as it inherits its rigour.

Epic integration is named, demonstrated at Epic expert group meetings, and covers both clinical decision support and patient education leaflets delivered at the point of care, with a dedicated EHR integration page and alignment across the UpToDate and Lexidrug content sets. Patient education material is offered in up to nineteen languages, which is a real interoperability property in a multilingual health system and one almost nothing else in this index provides. Held at B rather than A on specifics: no FHIR or SMART on FHIR detail was retrieved, no EHR beyond Epic is named in the material read, and no marketplace or Epic Toolbox credential was located, the latter mattering more since the Connexall record established Toolbox designation as the stronger integration credential.

The largest installed base of anything in this segment by a wide margin, with a reported three million clinician users across thousands of hospitals and localised sites across more than thirty countries. Delivery spans web, dedicated mobile applications for both the core product and Expert AI, personal subscriptions bought directly, and health system deployment through Enterprise Edition. Named reference: St. Luke's University Health Network, quoted through its Associate Chief Medical Information Officer. TWO THINGS HOLD IT AT B AND BOTH ARE CREDITED FOR BEING STATED RATHER THAN HIDDEN. Expert AI availability is geographically bounded, included in all United States personal subscriptions but only in Pro Plus and trainee subscriptions in Canada, and reaching health systems only through select Enterprise Edition accounts, so global reach of UpToDate is not global reach of the AI. And no data residency statement of any kind was retrieved despite operations across more than thirty countries, which for a European headquartered company selling into GDPR jurisdictions is a gap a buyer should close directly.

**THE MOST OPEN COMMERCIAL POSTURE IN THIS SEGMENT AND ONE OF THE MOST OPEN IN THE INDEX, BECAUSE PART OF THIS PRODUCT CAN SIMPLY BE BOUGHT.** A public webstore operates at store.uptodate.com with a See Pricing route, personal and trainee subscriptions are purchasable directly, and trainee rates are described as specially reduced against proof of status. A clinician can establish the cost of the AI enabled product without speaking to anyone, which is not true of a single other vendor graded in this segment. The scope of what is included is also stated plainly rather than left to a sales conversation: Expert AI is included in all United States personal subscriptions and in Pro Plus and trainee subscriptions in Canada. TWO REASONS IT IS B AND NOT A. The actual figures were not retrieved in this pass, so the openness is established structurally rather than by a captured rate. And enterprise pricing, which is what a health system actually buys and the only tier that reaches most clinicians, is entirely gated behind a sales conversation, so the transparent tier is the one that matters least to the institutional buyer this index serves.

Breadth is exceptional and explicitly enumerated rather than implied: physicians, physician assistants, nurse practitioners and advanced practice nurses, pharmacists, dentists, residents, fellows and students, and medical librarians, across health plans and payers, providers, hospital pharmacies, life sciences, virtual care technology companies and retail pharmacy, with localised sites in more than thirty countries. The trainee and medical university segments are substantial enough, alongside CME accrual inside the AI product, to justify the workforce and training cross listing. **TWO NEGATIVE SCOPE STATEMENTS ARE CREDITED BECAUSE THIS INDEX ASKS FOR THEM AND RARELY GETS THEM: the company states that Expert AI is available to individual subscribers only in the United States and Canada, and that CME credits earned inside Expert AI are not yet recognised by certain accrediting authorities.** Publishing what is not covered, and specifically what an earned credit will not yet count for, is the kind of disclosure that costs a vendor something. Held at B because coverage is asserted across every setting while no performance or accuracy evidence is published for any of them, so breadth of availability is established and breadth of demonstrated usefulness is not.